Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Operating Expenses (2023 - 2026)

Kura Oncology has reported Operating Expenses over the past 4 years, most recently at $97.1 million for Q1 2026.

  • Quarterly Operating Expenses rose 23.19% to $97.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $97.1 million through Mar 2026, down 64.23% year-over-year, with the annual reading at $371.1 million for FY2025, 50.2% up from the prior year.
  • Operating Expenses was $97.1 million for Q1 2026 at Kura Oncology, up from $78.8 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $97.1 million in Q1 2026 and troughed at $36.6 million in Q1 2023.
  • The 4-year median for Operating Expenses is $55.4 million (2024), against an average of $58.9 million.
  • Year-over-year, Operating Expenses skyrocketed 63.25% in 2024 and then increased 23.19% in 2026.
  • A 4-year view of Operating Expenses shows it stood at $46.8 million in 2023, then soared by 63.25% to $76.3 million in 2024, then increased by 3.24% to $78.8 million in 2025, then rose by 23.19% to $97.1 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Operating Expenses are $97.1 million (Q1 2026), $78.8 million (Q1 2025), and $76.3 million (Q4 2024).